REGENXBIO Q3 Earnings Call Highlights
Published . Updated .
Market Call
Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.
Get these market calls by email
The week's biggest market-moving stories, Congress trades and Trump posts, with the tickers they touch. Free, one email a week.
Free. We only use your email to send the digest, never sell or share it, and every email has a one-click unsubscribe link. See our privacy policy.
REGENXBIO (NASDAQ:RGNX) is approaching pivotal trial results for its eye disease gene therapy and preparing a U.S. application for its Duchenne muscular dystrophy treatment, executives said during the company’s third-quarter earnings call. The company and partner AbbVie expect
Directly affected
Indirectly affected
- XLV Health Care Select Sector SPDR
Health Care Select Sector SPDR holds the health sector that AbbVie belongs to, so it often moves with news about it.
- LLY Eli Lilly and+19.9% 30d
Eli Lilly and is a peer of AbbVie in pharmaceutical preparations; rivals often move on the same news.
- JNJ Johnson & Johnson+1.9% 30d
Johnson & Johnson is a peer of AbbVie in pharmaceutical preparations; rivals often move on the same news.
- MRK Merck+5.9% 19d
Merck is a peer of AbbVie in pharmaceutical preparations; rivals often move on the same news.
- ABT Abbott Laboratories+12.7% 30d
Abbott Laboratories is a peer of AbbVie in pharmaceutical preparations; rivals often move on the same news.
- PFE Pfizer+7.3% 30d
Pfizer is a peer of AbbVie in pharmaceutical preparations; rivals often move on the same news.
- AMGN Amgen+17.8% 30d
Amgen is a peer of Regenxbio in biological products, (no diagnostic substances); rivals often move on the same news.
- GILD Gilead Sciences+16.3% 30d
Gilead Sciences is a peer of Regenxbio in biological products, (no diagnostic substances); rivals often move on the same news.
Price reaction, T-5 to T+3
| Ticker | T-5 | T-3 | T-1 | T0 | T+1 | T+2 | T+3 |
|---|---|---|---|---|---|---|---|
| RGNX | -2.04% | +3.80% | base | +5.57% | after close | after close | after close |
| ABBVNo price data for this ticker | — | — | — | — | — | — | — |
| XLV | -0.05% | -0.52% | base | +0.18% | after close | after close | after close |
| LLYNo price data for this ticker | — | — | — | — | — | — | — |
| JNJNo price data for this ticker | — | — | — | — | — | — | — |
| MRKNo price data for this ticker | — | — | — | — | — | — | — |
| ABTNo price data for this ticker | — | — | — | — | — | — | — |
| PFENo price data for this ticker | — | — | — | — | — | — | — |
| AMGN | +1.22% | +0.14% | base | +0.08% | after close | after close | after close |
| GILD | +2.05% | -0.01% | base | +0.53% | after close | after close | after close |
Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.
REGENXBIO Q3 Earnings Call Highlights Yahoo Finance
Source: Yahoo Finance
This story
| Company | When | Move | Status |
|---|---|---|---|
| AMGN | that day | +0.08% | still updating |
| AMGN | three days earlier | +0.14% | final price |
| AMGN | five days earlier | +1.22% | final price |
| GILD | that day | +0.53% | still updating |
| GILD | three days earlier | -0.01% | final price |
| GILD | five days earlier | +2.05% | final price |
| RGNX | that day | +5.57% | still updating |
| RGNX | three days earlier | +3.80% | final price |
| RGNX | five days earlier | -2.04% | final price |
| XLV | that day | +0.18% | still updating |
| XLV | three days earlier | -0.52% | final price |
| XLV | five days earlier | -0.05% | final price |
Congressional trades in the stocks in this story
- Rep. Pete Sessions sold AbbVie (ABBV), worth $15,001 - $50,000 on 14 Sep 2026. That is 53 days before publication. Filed 18 Sep 2026. View the filing.
- Rep. Rohit Khanna sold AbbVie (ABBV) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 63 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Rohit Khanna bought Eli Lilly (LLY) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 63 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Thomas H. Kean Jr sold Johnson & Johnson (JNJ), worth $1,001 - $15,000 on 30 Sep 2026. That is 37 days before publication. Filed 30 Oct 2026. View the filing.
- Rep. Rohit Khanna bought Johnson & Johnson (JNJ) (held by a spouse), worth $1,001 - $15,000 on 25 Sep 2026. That is 42 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Lloyd Doggett bought Johnson & Johnson (JNJ), worth $1,001 - $15,000 on 8 Sep 2026. That is 59 days before publication. Filed 5 Oct 2026. View the filing.
- Rep. Maria Elvira Salazar sold Merck (MRK), worth $1,001 - $15,000 on 24 Sep 2026. That is 43 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Maria Elvira Salazar bought Merck (MRK), worth $15,001 - $50,000 on 19 Aug 2026. That is 79 days before publication. Filed 9 Sep 2026. View the filing.
- Rep. Pete Sessions sold Abbott Laboratories (ABT) (held by a spouse), worth $50,001 - $100,000 on 2 Oct 2026. That is 35 days before publication. Filed 27 Oct 2026. View the filing.
- Rep. Gilbert Cisneros bought Abbott Laboratories (ABT), worth $1,001 - $15,000 on 18 Sep 2026. That is 49 days before publication. Filed 12 Oct 2026. View the filing.
- Rep. Thomas H. Kean Jr sold Abbott Laboratories (ABT), worth $1,001 - $15,000 on 17 Sep 2026. That is 50 days before publication. Filed 30 Oct 2026. View the filing.
- Rep. Rohit Khanna sold Pfizer (PFE) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 63 days before publication. Filed 7 Oct 2026. View the filing.
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
How solid “REGENXBIO Q3 Earnings Call Highlights” looks
12 out of 100Price not final
“REGENXBIO Q3 Earnings Call Highlights” scores 12 out of 100. The score uses 1 sources. The price is not final yet.